Atezolizumab With or Without Radiotherapy for Advanced Squamous Cell Carcinoma of the Penis (The PERICLES Study): A Phase II Trial ascopubs.org/doi/10.1200/JC… @Hielke_Martijn Oscar Brouwer Uromigos Journal of Clinical Oncology Tom Powles Andrea Necchi Maarten Albersen The Netherlands Cancer Institute Petros Grivas

Join to our project! More details soon

Este viernes organizamos el evento: We are all CENL: Science is for Everyone”. En él trataremos diferentes temas como ☑️La mujer en Ciencia ☑️LGBTQ+ en Ciencia ☑️Diversidad cultural y técnica en Ciencia

🟣 last chance to register 🟣 Will you join us tomorrow (15h) in Utrecht, to discuss persistent inequities in Science? Registration is free: docs.google.com/forms/d/e/1FAI…

Glad to help! #GettingThingsDone method has helped me A LOT! If you feel drowned my dozens of tasks, maybe it's worth a try. Go to the free #Notion template I self-designed (small tutorial included🙃) Have a quick look at the template👇👁️! acortar.link/b4PZcu

👏👏👏

nature.com/articles/s4146… Great work by Alberto Gil Jimenez to understand why CD8 T-cell density is not necessarily predictive for IO response in UC. It's the distance that matters! The Netherlands Cancer Institute Tom Powles Christian Blank MarleenKokLab Petros Grivas Antoni van Leeuwenhoek @MattGalsky

To predict whether treatment with checkpoint inhibitors will work, you need to take the tumor environment into consideration, PhD Candidate Alberto Gil Jimenez proposes. Antoni van Leeuwenhoek TU Delft He will defend his thesis on November 19 ➡️ bit.ly/4fmHv3j

Nuevo doctor en la comunidad CENL 🍏 Alberto Gil Jimenez ha defendido su tesis sobre el rol del microambiente tumoral en el cáncer urotelial para determinar la respuesta a los tratamientos preoperatorios, como quimioterapia o inhibidores de puntos de control inmunológico. ¡Felicidades!